Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Briakinumab (ABT-874), a fully human anti-IL-12/23p40 monoclonal antibody, selectively targets and neutralizes IL-12 and IL-23. This compound is utilized in the research of various autoimmune disorders, including rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry |
Description | Briakinumab (ABT-874), a fully human anti-IL-12/23p40 monoclonal antibody, selectively targets and neutralizes IL-12 and IL-23. This compound is utilized in the research of various autoimmune disorders, including rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis [1]. |
Molecular Weight | N/A |
CAS No. | 339308-60-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Briakinumab 339308-60-0 inhibitor inhibit